Ginkgo Bioworks Holdings (DNA) Operating Margin (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Operating Margin of 366.51% for Q1 2026, down 15471.0% year-on-year from N/an in Q1 2025, and down 73.0% on a QoQ basis from 211.86% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Operating Margin data on file, last reported at 366.51% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 15471.0% year-over-year to 366.51%; the trailing twelve-month figure through Mar 2026 stood at 210.66% (down 711.0% YoY), and the FY2025 full-year result was 185.29%, up 6125.0% from the prior year.
- Operating Margin for Q1 2026 stood at 366.51%, down from 211.86% in the prior quarter.
- Across five years, Operating Margin topped out at 61.99% in Q3 2024 and bottomed at 986.38% in Q3 2022.
- The 5-year median for Operating Margin is 267.34% (2023), against an average of 347.85%.
- Peak annual rise in Operating Margin reached 89966 bps in 2022, while the deepest fall reached 95202 bps in 2022.
- A 5-year view of Operating Margin shows it stood at 234.89% in 2022, then sank by 118 bps to 512.49% in 2023, then jumped by 54 bps to 236.29% in 2024, then climbed by 10 bps to 211.86% in 2025, then tumbled by 73 bps to 366.51% in 2026.
- The last three Operating Margin figures came in at 366.51% (Q1 2026), 211.86% (Q4 2025), and 231.78% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -366.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -366.51% |
| Dec 31, 2025 | -211.86% |
| Sep 30, 2025 | -231.78% |
| Jun 30, 2025 | -132.13% |
| Mar 31, 2025 | -211.80% |
| Dec 31, 2024 | -236.29% |
| Sep 30, 2024 | -61.99% |
| Jun 30, 2024 | -396.66% |
| Mar 31, 2024 | -469.12% |
| Dec 31, 2023 | -512.49% |
| Sep 30, 2023 | -516.68% |
| Jun 30, 2023 | -228.57% |
| Mar 31, 2023 | -267.34% |
| Dec 31, 2022 | -234.89% |
| Sep 30, 2022 | -986.38% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |
| Jun 30, 2021 | -137.38% |
| Mar 31, 2021 | -129.52% |
| Dec 31, 2020 | -174.33% |
| Sep 30, 2020 | -258.71% |